CNN’s ‘Mission: Ahead’ meets the pioneers pushing the boundaries of technology to save lives
A week of special coverage airs April 25-29, with a 30-minute program airing May 1 HONG KONG, April 27, 2022 /PRNewswire/ -- CNN's 'Mission: Ahead' is a brand-new cross-platform series which explores the world's biggest challenges - from climate change to disease - and profiles the fearless and impassioned leaders who are tackling them with innovative projects that our...
RVAC Medicines, a CBC-Incubated mRNA Platform Company, Raises US$140 Million to Expand R&D and Manufacturing Capacity
Series B financing led by CBC with participation from Temasek's Pavilion Capital, EDBI and GS Holdings RVAC plans to build R&D center and manufacturing facilities in Singapore and China SINGAPORE, April 27, 2022 /PRNewswire/ -- RVAC Medicines Pte. Ltd. ("RVAC"), an emerging messenger RNA (mRNA) platform company incubated in Singapore by CBC Group ("CBC"), today announced the completion of...
Antengene Announces Submission to the Human Research Ethics Committee in Australia for a Phase I Trial of ATG-018
Developed in-house by internal R&D Team at Antengene, ATG-018 is an orally-available, small molecule ATR inhibitor that targets DNA Damage Response (DDR) pathways. The Phase I study will evaluate the safety, pharmacology and preliminary efficacy of ATG-018 in patients with advanced solid tumors and hematologic malignancies. ATG-018 has the potential as the...
VISTA Eye Specialist (VISTA) Opens its 12th Outlet with Massive Success
PETALING JAYA, Malaysia, April 27, 2022 /PRNewswire/ -- VISTA officially opened in Malaysia's 5th largest city - Ipoh, marking its 12th outlet in the country. It presently has seven branches in Klang Valley, three in Penang (Northern Malaysia) and one in Johor Bahru (Southern Malaysia). VISTA’s 12th Branch at Bond Square, Ipoh "VISTA Ipoh was opened on...
Taiyo Corporation Introducing OPELAIII “Subscription Style” Rental Purchase Plan
Once subscription ends, the units can be redistributed as used equipment to countries with strong demands and thereby meet SDGs requirement TOKYO, April 27, 2022 /PRNewswire/ -- Taiyo Corporation (Headquarter: Tokyo, Japan / President: Mariko Koizumi), the manufacturer of Wearable Surgical Lighting System OPELAIII, is launching a subscription style long-term rental service coined "OPELAIII Smart Plan" and begins accepting applications...
Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-400945 for the Treatment of Acute Myeloid Leukemia
NEW YORK and HONG KONG, April 27, 2022 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for unmet needs in cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to CFI-400945, a first in class inhibitor of Polo-like kinase 4 (PLK4), for the treatment of adult patients with relapsed or...
FDA Approves Direct Biologics to Proceed with a Landmark Phase 3 Acute Respiratory Distress Syndrome (ARDS) Trial
AUSTIN, Texas, April 27, 2022 /PRNewswire/ -- Direct Biologics, a regenerative biotechnology company with a groundbreaking extracellular vesicle (EV) platform technology, announced today that the FDA has approved the company to proceed with its Phase 3 clinical trial using its investigational EV drug, ExoFlo, to treat Acute Respiratory Distress Syndrome (ARDS) due to Covid-19. Direct Biologics is the first...
The Korea Society of Ginseng Announces Red Ginseng Reduces Fatigue and Stress
- Fatigue and helplessness are the most common after-effects of COVID-19. - The Korea Society of Ginseng presented the results of a study on the effect of red ginseng on improving fatigue and lethargy. SEOUL, South Korea, April 26, 2022 /PRNewswire/ -- The Korea Society of Ginseng disclosed the results of a study titled The Effect of Red Ginseng on...
Seegene unveils world’s first commercialized ‘3 Ct’ PCR assay
Provides Ct value of three targets in one channel; '3 Ct' PCR assay to launch in H1 "Dream MDx technology" developed based on Seegene's 20-year expertise; combines 19 different patented technologies, including DPO™, TOCE™, MuDT™ '3 Ct' to lay foundation for automated syndromic testing and make MDx more accessible ...
PharmAbcine Announces Positive Results for Its Novel TIE2-Activating Antibody in GLP Toxicology Study
DAEJEON, South Korea, April 26, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today the positive results from the GLP toxicology study of PMC-403, the Company's novel TIE2-activating antibody. PMC-403 can stabilize and repair damaged and pathologically leaky blood vessels,...
